You are here: Industry Insights > AstraZeneca

News List

AstraZeneca spinout Entasis files for $86M IPO to fund antibiotic phase 3 fiercebiotech
August 21, 2018
Entasis Therapeutics has filed to raise up to $86 million through an IPO. The AstraZeneca spinout is seeking the money to fund a phase 3 trial of a drug to overcome bacterial resistance to beta-lactams.
Ironwood returns US Zurampic rights to AstraZeneca, announces operational cuts pharmafile
August 09, 2018
Ironwood Pharmaceuticals has revealed that it has taken the decision to hand the rights for gout therapy Zurampic (lesinurad) back to AstraZeneca, terminating an agreement between the two firms that was struck in 2016.
AstraZeneca to pay $110m to settle allegations of fraudulent marketing in Texas pharmafile
August 09, 2018
AstraZeneca has backed down in a dispute with the State of Texas over allegations it had defrauded the state’s Medicaid programme to illegitimately market two of its drugs, agreeing to pay a settlement of $110 million.
Texas spanks AstraZeneca as a repeat offender in settling Seroquel, Crestor whistleblower suits fiercepharma
August 09, 2018
Add another $100 million or so to AstraZeneca’s billion-dollar tally of Seroquel legal settlements. The pharma giant has agreed to settle a Texas Medicaid fraud lawsuit that claimed it hawked the powerful antipsychotic for unapproved uses......
AstraZeneca settles US Seroquel/Crestor lawsuits for $110 million pharmatimes
August 09, 2018
AstraZeneca has agreed to pay $110 million to the state of Texas to settle lawsuits relating to the drugs Seroquel and Crestor.
Ironwood returns US Zurampic rights to AstraZeneca, announces operational cuts pharmafile
August 08, 2018
Ironwood Pharmaceuticals has revealed that it has taken the decision to hand the rights for gout therapy Zurampic (lesinurad) back to AstraZeneca, terminating an agreement between the two firms that was struck in 2016.
AstraZeneca and Merck obtain EMA orphan status for selumetinib pharmaceutical-technology
August 07, 2018
AstraZeneca and Merck (MSD) have secured the European Medicines Agency orphan designation for a MEK 1/2 inhibitor called selumetinib to treat neurofibromatosis type 1 (NF1).
Ironwood abandons deal with AstraZeneca for lesinurad, once hoped to be a gout blockbuster fiercebiotech
August 07, 2018
Ironwood Pharmaceuticals has decided to walk away from its 2016 deal to license AstraZeneca’s billion-dollar gout treatment lesinurad in the U.S., following poor market performance of the drug, as Ironwood continues its march toward splitting into two sep
Medpacto inks deal with AstraZeneca biospectrumasia
August 03, 2018
Under the terms of the agreement, MedPacto and AstraZeneca will collaborate on a non-exclusive basis to evaluate the combination of the two drugs in NSCLC
Justice Department probes claims that AstraZeneca bribed Iraqi terrorists to win contracts fiercepharma
August 01, 2018
More than 100 veterans last year filed a bombshell lawsuit against several drugmakers, alleging they financed terrorism by paying bribes to win contracts with the Iraqi Ministry of Health.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 80 81 Next page